Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TDNM
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
TDNM is a synthetic analogue of cord factor, specifically 6,6'-dideoxy-6,6'-bis-mycoloylamino-alpha,alpha-trehalose. It is described as a less toxic cord factor analogue that has demonstrated potent antitumour activity, particularly when combined with other immunomodulatory agents like 6-O-stearoyl muramyldipeptide (L18-MDP) or synthetic lipid A of Escherichia coli (compound 506). Its mechanism of action is related to its immunomodulatory properties, leading to the regression of transplantable line-10 hepatocellular carcinoma in experimental models.
- Other names
- 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose
Beyond the preview
Go deeper on TDNM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TDNM.